Abstract: Provided herein are methods and compositions for determining whether a patient suffers from systemic amyloidosis, comprising detecting the presence of a misfolded or aggregated protein in a tissue of the patient, wherein the detecting comprises contacting the misfolded or aggregated transthyretin protein with a compound described herein. In some embodiments, the misfolded or aggregated protein is transthyretin.